A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Registration Number
- NCT00372931
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Adult patients of either sex and any race with open-angle glaucoma or ocular hypertension; logMAR visual acuity not worse than 0.60; additionally clinically relevant ophthalmic or systemic conditions may be excluded
Exclusion Criteria
- Under 18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mean IOP change from baseline
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of AL-37807 in reducing intraocular pressure for open-angle glaucoma and ocular hypertension?
How does AL-37807 compare to prostaglandin analogs and beta-blockers in efficacy and safety for glaucoma treatment?
What biomarkers are associated with response to AL-37807 in patients with primary open-angle glaucoma or ocular hypertension?
What adverse events were observed in the Phase II trial of AL-37807 (NCT00372931) and how were they managed?
Are there any combination therapies involving AL-37807 for managing refractory open-angle glaucoma or ocular hypertension?
Trial Locations
- Locations (1)
San Antonio Site
🇺🇸San Antonio, Texas, United States
San Antonio Site🇺🇸San Antonio, Texas, United States